GET DAILY SIGNALSTilray Brands (TLRY) Shares Decline -18.7% Over the Past 30 Days After Earnings Miss
Key Takeaways
- TLRY declined roughly 18.7% over the last 30 days, falling from about $3.59 in early October to near $2.92.
- The selloff followed fiscal Q1 2027 results that missed revenue and Adjusted EBITDA expectations despite record top-line performance.
- Weakness in Canadian adult-use cannabis, price compression, and a 13% year-over-year decline in cannabis revenue offset strong beverage and distribution growth.
- Several analysts trimmed price targets while maintaining their ratings, reinforcing cautious sentiment on the stock.
- Over the trailing three months, the shares have fallen roughly 35%, extending a broader multi-month downtrend.
- Tilray reaffirmed full-year Adjusted EBITDA guidance of $68–75 million and ended the quarter in a net cash position.
Tilray Brands (TLRY) Company Overview and Market Position
Tilray Brands, Inc. is a global consumer packaged goods company that has evolved well beyond its cannabis roots. The company operates across four primary segments: cannabis, beverage alcohol, pharmaceutical distribution, and wellness. Its beverage portfolio, anchored by the BrewDog craft beer acquisition, has made TLRY one of the larger craft brewers in the United States and the United Kingdom, while its distribution arm focuses largely on pharmaceutical wholesale in Germany. Cannabis operations span Canada and international medical markets, supported by cultivation facilities in Canada, Portugal, and Germany. Investors follow TLRY for its diversification strategy, international growth in Europe, and the long-running debate over when broader U.S. cannabis legalization might materialize. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Tilray Brands (TLRY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TLRY shares declined approximately 18.7%, moving from about $3.59 to near $2.92. The move was not a single-day event but a steady grind lower punctuated by sharp down sessions around the company's quarterly report and subsequent analyst revisions.
The near-term decline is part of a longer trend. Over the trailing quarter, the stock has fallen roughly 35%, extending a slide from levels near $4.50 in early August. This multi-month downtrend reflects persistent investor concern about organic growth, profitability, and the competitive Canadian cannabis market, even as the company's beverage and distribution businesses continue to scale.
What Drove TLRY Stock Price in the Last 30 Days
The primary catalyst was Tilray's fiscal first-quarter 2027 earnings report, released in early October. The company delivered record net revenue of $257.1 million, up roughly 23% year over year, but the figure missed consensus estimates of about $266.8 million. Adjusted EBITDA of $9.2 million also came in below analyst expectations, and the company cited global fuel surcharges as a headwind.
Beneath the headline, the details weighed on sentiment. Beverage revenue surged 82% to $101.5 million, helped by BrewDog, and distribution revenue rose 14% to $84.3 million. However, cannabis revenue declined 13% year over year to $56.1 million, with Canadian adult-use sales falling 16% amid intense competition and price compression. International cannabis revenue rose 21%, but not enough to offset domestic softness.
Analyst activity amplified the move. Haywood Securities maintained a Hold rating with a $4.00 target, while Roth/MKM lowered its target to $9.00 and Canaccord Genuity reduced its target to $4.00. Two analysts downgraded the stock during the month with no upgrades, contributing to negative momentum.
What Drove TLRY Stock Performance Over the Last Quarter
The quarterly decline is rooted in a broader narrative: a competitive, oversupplied Canadian adult-use market, fading expectations for near-term U.S. legalization, and ongoing questions about the company's path to consistent profitability. Tilray has been building scale through acquisitions, but investors have increasingly focused on organic growth and cash flow rather than top-line expansion.
The company's diversification has been a double-edged story. Beverages and distribution have become meaningful growth engines and provide revenue stability, yet the core cannabis segment continues to face pricing pressure and excise-tax burdens. This dynamic has kept the stock under sustained selling pressure, with the shares hitting multi-year lows during the period. From what I see, this remains a key area to monitor closely.
TLRY Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape TLRY's trajectory in the months ahead. First, investors will watch whether Canadian adult-use sales stabilize as management introduces new cultivars and products later in fiscal 2027. Second, the company's ability to convert beverage-led revenue growth into stronger margins and consistent cash flow will remain a focal point, particularly as BrewDog integration continues.
International medical cannabis growth across Europe, including Germany, represents another key driver, as does the pace of debt reduction. Macroeconomic conditions, excise-tax policy, and any shift in U.S. federal cannabis regulation could also influence sentiment. Finally, analyst revisions and whether the company can meet its reaffirmed Adjusted EBITDA guidance of $68–75 million will be closely monitored by the market. I’m watching this closely as new data emerges.
Exploring Tickeron AI Trading Bots for Additional Perspective
In my own research process, I often turn to Tickeron’s AI Trading Bots to test systematic approaches on names like TLRY. The platform offers hundreds of bots trading thousands of tickers, with a curated Trending AI Robots section highlighting top-performing strategies across different timeframes and styles. This gives me a way to compare momentum-based tactics against longer-term trend-following methods without building everything from scratch. It has helped me gain additional context on how automated systems are currently positioned around the stock.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TLRY turns positive, indicating new upward trend
TLRY saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 63 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, 39 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (7.254). P/E Ratio (-2.679) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric
Advertisement